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A related editorial, “Pick the Winner Designs in Phase II Cancer Clinical Trials” by Sumithra J. Mandrekar
appears on page 5 of this issue.
Background: Gemcitabine and carboplatin combination therapy is
an active and tolerable regimen in the treatment of non–small-cell
lung cancer (NSCLC). Twenty-eight– and 21-day regimens without
day-15 administration of gemcitabine are common; however, it
remains unclear which offers the optimal therapeutic index.
Methods: This trial evaluated two schedules of the combination of
gemcitabine and carboplatin: gemcitabine (1100 mg/m2 on days 1
and 8) plus carboplatin (area under the curve 5 on day 8) every 28
days, or gemcitabine (1000 mg/m2 on days 1 and 8) plus carboplatin
(area under the curve  5 on day 1) every 21 days. Eligible patients
in this trial had stage IIIB (with malignant pleural effusion) or stage
IV NSCLC with no prior chemotherapy. The primary objective was
to evaluate progression-free survival, with secondary objectives of
overall survival, response rate, and toxicity.
Results: One hundred patients were randomized and enrolled from
October of 2000 to January of 2002 into this multi-institutional
study (48 for the 28-day regimen and 52 for the 21-day regimen).
Baseline demographics were well matched, and a majority of pa-
tients (85%) enrolled with stage IV disease. Median progression-free
survival and response rates were 3.8 months and 22.9%, respec-
tively, with the 28-day regimen, and 4.9 months and 40.4%, respec-
tively, with the 21-day regimen. Median survival was 8.7 months
with the 28-day regimen and 8.0 months for the 21-day regimen.
One- and 2-year survival rates were 34.7% and 8.7%, respectively,
with the 28-day regimen, and 36.5% and 16.8%, respectively, with
the 21-day regimen. Differences in progression-free survival (log-
rank statistic, p  0.5786), response rate (Fisher’s exact test, p 
0.0859) and overall survival (log-rank statistic, p  0.3568) were
not statistically significant. Grade 3 to 4 hematologic toxicities
occurred with a greater frequency in the 21-day regimen. No grade
3 to 4 nonhematologic toxicity (except nausea/vomiting with the
28-day regimen) was observed in more than 10% of patients in
either treatment arm.
Conclusion: Gemcitabine plus carboplatin is active and well toler-
ated in advanced NSCLC. Both regimens may be considered for
further study. Although the 21-day regimen appeared to be associ-
ated with preferable outcomes, differences between treatment
groups were not statistically significant.
Key Words: Gemcitabine, Carboplatin, Non–small-cell lung can-
cer, Combination therapy, Randomized phase II trial.
(J Thorac Oncol. 2006;1: 19–24)
In the United States, it is estimated that there will be 171,500new cases of and 156,100 deaths resulting from lung cancer
each year, making it the most common cause of cancer-
related death in the United States.1 Non–small-cell lung
cancer (NSCLC) constitutes 75% to 80% of all lung cancers.2
Because the majority of patients present with advanced dis-
ease, overall survival and prognosis are poor.
Single-agent chemotherapy produces modest response
rates in advanced NSCLC. Although two-drug combinations
are superior to monotherapy, the addition of a third drug does
not improve survival outcomes.3 Platinum-containing dou-
blets are now considered standard for the treatment of good
performance status patients with advanced NSCLC.4–6 Based
on overall survival or progression-free survival, however, no
particular regimen has established superior efficacy.7,8 There-
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fore, the choice of chemotherapy in advanced NSCLC is
often based on potential treatment-related toxicities.
Early trials examining the combination of gemcitabine
and carboplatin in NSCLC used various treatment sched-
ules.9–11 Regimens consisted of (1) gemcitabine at a dose of
1000 mg/m2 on days 1 and 8 with carboplatin at an area under
the curve (AUC) of 5.5 on day 1; (2) gemcitabine at 1000
mg/m2 on days 1, 8, and 15, with carboplatin dosed at an
AUC of 5.2 on day 1; and (3) gemcitabine at 1200 mg/m2 on
days 1 and 8 and carboplatin at an AUC of 5.0. In these small
trials, response rates ranged from 21% to 50%, with median
survival times of approximately 11 months.9–11
Carrato et al. compared two different schedules of
gemcitabine and carboplatin in NSCLC: a 21-day schedule
with gemcitabine (1000 mg/m2) given on days 1 and 8 and a
28-day schedule with gemcitabine on days 1, 8, and 15, with
carboplatin (AUC 5) on day 1 in both schedules.11,12 In these
trials, there was less hematologic toxicity on the 21-day sched-
ule, with no difference in efficacy. With the 28-day regimen,
neutropenia and thrombocytopenia occurred in the majority of
patients primarily on or near day 15 of each cycle. On the basis
of these results, the 21-day regimen was favored.13
In a dose-escalation phase I/II study, Iaffaioli et al.
studied gemcitabine (1100 mg/m2) on days 1 and 8 and
carboplatin (AUC 5) on day 8 of a 28-day cycle.14 At this
dose, 33% and 8% of the patients had grade 3 to 4 neutro-
penia and thrombocytopenia, respectively, suggesting that
this was a well-tolerated regimen. In the study, the objective
response rate was 50%, the median duration of response was
13 months, and the median overall survival was 16 months.
The 28-day regimen recommended by Iaffaioli et al.
and the more conventional 21-day regimen are both widely
used to treat advanced NSCLC, but it remains unclear which
offers the optimal therapeutic index. The purpose of this study
was to use the dosing from these two schedules for comparison
in the context of a phase II, randomized clinical trial.
PATIENTS AND METHODS
Patient Eligibility
This multicenter phase II trial randomized patients into
treatment arms that received a 28- or 21-day regimen of
gemcitabine plus carboplatin. Patients were required to have
histologically confirmed stage IIIB (with malignant pleural
effusion) or stage IV NSCLC and be 18 years of age or older,
be chemotherapy naive, and have measurable (lesions that
can be accurately measured as 20 mm in at least one
dimension) or assessable disease. Patients were also required
to have adequate hematologic (white blood cell count3500/
mm3, platelet count 100,000/mm3, granulocyte count
1500 mm3, hemoglobin 9 g/liter, and hematocrit 30%),
hepatic (serum bilirubin 1.25 times the institutional upper
normal limit and aspartate transaminase 2.5 times the
institutional upper normal limit), and renal (serum creatinine
2 mg/dl or calculated creatinine clearance 50 ml/min)
function and an Eastern Cooperative Oncology Group Per-
formance Status of 0 or 1. No prior radiation to the site to be
followed for response was allowed, and any prior radiation
therapy had to be completed 3 or more weeks before enroll-
ment. All patients were required to sign informed consent and
use an approved method of contraception if of childbearing
potential.
This study was performed in accordance with the princi-
ples stated in the Declaration of Helsinki and regulatory stan-
dards for good clinical practice. The institutional review board of
each participating center reviewed and approved this study.
Treatment Plan
Patients were randomized to receive one of the follow-
ing regimens:
Arm A (28-day regimen, as recommended by
Iaffaioli et al).
Gemcitabine, 1100 mg/m2, was administered as a 30-
minute intravenous infusion on days 1 and 8 followed by
carboplatin at a dose of AUC 5 administered over 30 minutes
as an intravenous infusion on day 8. This cycle was repeated
every 28 days until disease progression.
Arm B (21-day regimen).
Gemcitabine, 1000 mg/m2, was administered as a 30-
minute intravenous infusion on days 1 and 8 followed by
carboplatin at a dose of AUC 5 administered over 30 minutes
as an intravenous infusion on day 1. This cycle was repeated
every 21 days until disease progression.
The total number of cycles administered was at the
discretion of the treating physician. No other chemotherapy,
immunotherapy, antitumor hormonal therapy (excluding con-
traceptives and replacement steroids), radiation therapy, or
experimental medications were permitted while the patients
were on the study.
On day 8, platelets, granulocytes, and nonhematologic
toxicities were clinically evaluated. If granulocytes were
between 500 and 1000/mm3 or platelets were between 50,000
and 75,000/mm3, dosages were to be reduced by 25%. If
granulocytes were less than 500/mm3 or platelets were less
than 50,000/mm3, treatment was to be withheld. After grade
3 or 4 nonhematologic events, treatment was withheld at the
discretion of the physician. If toxicities resolved to grade 2 or
lower, resumption of treatment was allowed during the subse-
quent cycle. For subsequent cycles, day-1 treatment was only
administered when neutrophil counts were greater than 1000/
mm3, platelet counts were greater than 100,000/mm3, and all
nonhematologic toxicities resolved to grade 2 or lower.
Response Criteria
Tumor response assessments were based on modified
Response Evaluation Criteria in Solid Tumors.15 Complete
response was defined as the disappearance of all known
disease (target and nontarget lesions) determined by two
observations not less than 4 weeks apart. A partial response
(PR) was defined as a 30% reduction from baseline in the sum
of the longest diameter (LD) of the target lesions taking as
reference the baseline LD sum and a lack of disease progres-
sion in nontarget lesions. Progressive disease (PD) was de-
fined as the development of any new lesions or an increase of
20% in the LD sum of target lesions taking as reference the
smallest sum LD recorded since the treatment started. Pa-
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tients with stable disease (SD) did not meet the criteria for PR
or PD.
Disease progression was defined as the time from the
date of randomization to the first date of documented pro-
gression or death from any cause. Progression-free survival
was censored at the date of the last follow-up visit for patients
who were still alive and whose disease had not progressed.
Overall survival time was defined as the time from the date of
randomization to the date of death from any cause. Overall
survival time was censored at the date of the last follow-up
visit for patients who were still alive.
Statistical Analysis/Randomization
This trial randomized 100 patients with equal probabil-
ity to either of the two regimens. Patients were stratified by
stage of disease and gender. The stratification took place at
randomization, to ensure balance with respect to these char-
acteristics in the two arms. The primary analyses was un-
stratified, to avoid small numbers in the subgroups.
The sample size was chosen based on a selection design
that used progression-free survival as the primary endpoint.
The selection design assumed that a primary goal of the trial
was to select a regimen for a larger, phase III trial. For this
reason, type I, or alpha, error was not controlled under this
design: the procedure was designed to select the regimen with
the observed numerical advantage in progression-free survival
based on a positive or negative value for the one-sided log-rank
statistic. Assuming a hazard ratio of 1.2 or greater, and assuming
at least 85 treatment failure events, there was at least an 80%
chance of correctly selecting the less hazardous ratio.
Kaplan-Meier estimates were calculated for the produc-
tion of survival curves.16 Estimates of 1- and 2-year survival
were computed from these curves, with 95% confidence
intervals (CIs). Demographic characteristics were collected to
determine the comparability of the two treatment groups.
Adverse events were assessed using National Cancer Institute
Common Toxicity Criteria version 2.0.
RESULTS
One hundred patients were enrolled from October of
2000 to January of 2002 into this multi-institutional study (48
for the 28-day regimen and 52 for the 21-day regimen). All
patients enrolled into the study were analyzed for toxicity,
survival, time to progression, and best tumor response.
Patient Characteristics
Patient characteristics at baseline were similar between
treatment arms (Table 1). Median age was 66 years (range,
38–82 years) for the 28-day regimen and 67 years (range,
44–82 years) for the 21-day regimen. The majority of pa-
tients for both groups were men and had an Eastern Cooper-
ative Oncology Group Performance Status of 1, Caucasian
racial origin, stage IV disease, and a histologic diagnosis of
adenocarcinoma.
Dose Administration
Patients on the 28-day regimen received a total of 180
cycles of treatment (median, 4.00; mean, 3.75; range, 1–10),
compared with 249 cycles (median, 6.00; mean, 4.79; range,
1–12) for the 21-day regimen. There were a total of 24 dose
interruptions (median, 0.00; mean, 0.50; range, 0–3) and 27
dose reductions (median, 0.0; mean, 0.56; range, 0–4) for the
28-day regimen, compared with 39 dose interruptions (median,
0.0; mean, 0.75; range, 0–4) and 43 dose reductions (median,
0.0; mean, 0.83; range, 0–4) for the 21-day regimen.
Progression-Free Survival
Progression-free survival for both treatment groups is
summarized in Figure 1. Median progression-free survival
was 3.8 months (95% CI, 3.2–6.1 months) for the 28-day
regimen and 4.9 months (95% CI, 3.9–5.5 months) for the
21-day regimen. At 1 year, disease had not progressed in
FIGURE 1. Kaplan-Meier summary of progression-free sur-
vival.
TABLE 1. Patient Characteristics
28-Day Regimen
(n  48) (%)
21-Day Regimen
(n  52) (%)
Median age, yr (range) 66 (38–82) 67 (44–82)
Gender
Male 30 (62.5) 31 (59.6)
Female 18 (37.5) 21 (40.4)
ECOG PS
0 17 (35.4) 19 (36.5)
1 31 (64.6) 33 (63.5)
Racial origin
Caucasian 44 (91.7) 46 (88.5)
Other 4 (8.3) 6 (11.5)
Stage
IIIb 7 (14.6) 8 (15.4)
IV 41 (85.4) 44 (84.6)
Histology
Adenocarcinoma 25 (52.1) 28 (53.8)
Large-cell 2 (4.2) 1 (1.9)
Non–small-cell 14 (29.2) 7 (13.5)
Squamous 7 (14.6) 16 (30.8)
ECOG PS, Eastern Cooperative Oncology Group Performance Status.
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4.6% (95% CI, 0.0–10.7%) of patients in the 28-day regimen
and 9.8% (95% CI, 1.6–18.0) in the 21-day regimen. Differ-
ences in median progression-free survival between the two
groups were not statistically significant (log-rank statistic,
p  0.5786).
Tumor Response
Objective tumor response is summarized in Table 2.
The overall response rate was 22.9% (95% CI, 12.0–37.3%)
for the 28-day regimen and 40.4% (95% CI, 27.0–54.9%) for
the 21-day regimen. There was no statistically significant
difference in objective response between the two regimens
(Fisher’s exact test, p  0.0859). The 28-day regimen in-
cluded no patients with CR, 11 with PR, 21 with SD, and 13
with PD. The 21-day regimen included one patient with a CR,
20 with PR, 20 patients with SD, and 10 with PD.
Overall Survival
Median survival was 8.7 months (95% CI, 6.4–11.9
months) for the 28-day regimen and 8.0 months (95% CI,
5.9–11.4 months) for the 21-day regimen (Figure 2). One-
year survival was 34.7% (95% CI, 21.1–48.3%) for patients
receiving the 28-day regimen and 36.5% (95% CI, 23.5–
49.6%) for patients receiving the 21-day regimen. Two-year
survival for the 28-day and 21-day regimens was 8.7% (95%
CI, 0.6–16.8%) and 16.8% (95% CI, 6.5–27.1%), respec-
tively. Differences in median survival time between the two
groups were not statistically significant (log-rank statistic,
p  0.3568).
Toxicity Summary
As shown in Tables 3 and 4, principal grade 3 to 4
toxicities in both treatment arms were hematologic. Grade 3
to 4 hematologic toxicities were anemia (25.0% versus
4.2%), neutropenia (48.1% versus 27.1%), and thrombocyto-
penia (50.0% versus 37.5%) in the 21-day and 28-day regi-
mens, respectively. A single patient receiving the 21-day
regimen in the study experienced grade 3 neutropenic fever.
No grade 3 to 4 nonhematologic toxicity (except nau-
sea/vomiting with the 28-day regimen) was observed in more
than 10% of patients in either treatment arm. Grade 2 alope-
cia was experienced by three patients (6.3%) in the 28-day
regimen and two patients (3.8%) in the 21-day regimen.
DISCUSSION
We present results of the first randomized study to
characterize the efficacy and tolerability of carboplatin and
gemcitabine when administered according to the Iaffaioli et
al.14 or 21-day schedules. Both schedules delivered toxicity
and efficacy results that are comparable to other platinum
doublets in advanced NSCLC.
There were no statistically significant differences be-
tween schedules with respect to progression-free survival,
overall survival (median, approximately 8 months for both
schedules), or objective response rates. The insignificant
difference in response rates between schedules may have
been attributable to small sample size. Although there was no
statistical superiority, however, progression-free survival,
1-year survival, and 2-year survival favored the 21-day reg-
imen. Nearly twice as many patients on the 21-day regimen
were alive at 2 years as compared with the 28-day regimen.
The primary safety concern with both regimens was hema-
tologic; myelosuppression appeared to be more pronounced
with the 21-day regimen, yet the rate of neutropenic fever
was exceptionally low.
Recent studies using combination chemotherapy with
gemcitabine and carboplatin in NSCLC show response rates
in the range of 30% to 50% and median survival ranging from
6 to 16 months.4,10,12,14,17–24 For these trials, the main dose-
limiting toxicities were hematologic. Recent review articles
have summarized the results of trials using 28- and 21-day
schedules of gemcitabine and carboplatin.25–27
Many previous studies have used the 21-day regimen of
gemcitabine plus carboplatin used in the current trial, with
most achieving response rates of greater than 30% and
median survival exceeding 9 months.12,17,28–30 Although the
response rates observed in this study are comparable, median
survival was slightly less as compared with historical results.
This is likely related to the high proportion (85%) of patients
enrolled in this study with advanced stage IV disease.
The current study was unable to duplicate the initial
promising results of the 28-day regimen of Iaffaioli et al.
(objective response rate, 50%; median duration of response, 13
TABLE 2. Objective Response
28-Day Regimen
(n  48) (%)
21-Day Regimen
(n  52) (%)
Complete response 0 1(1.9)
Partial response 11 (22.9) 20 (38.5)
Stable disease 21 (43.8) 20 (38.5)
Progressive disease 13 (27.1) 10 (19.2)
Unknown 3 (6.3) 1 (1.9)
Overall response rate, % 22.9 40.4
95% CI 12.0–37.3 27.0–54.9
FIGURE 2. Kaplan-Meier summary of overall survival.
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months; median overall survival, 16 months). However, as noted
by Mott et al., the exceptional results of Iaffiaioli et al. were
likely attributable to the inclusion of patients with “dry” stage
IIIB disease.31 Using the same 28-day regimen as the current
study and similar inclusion criteria, Mott et al. reported a median
survival of 8.3 months, nearly matching that of the current study.
Comparable to this study, 83% of the patients in the study by
Mott et al. enrolled with stage IV disease.31
Data obtained in this trial are also comparable to that of
a prior 498-patient surveillance trial reported by Obasaju et
al.32 In that study, patients were nonrandomly assigned on the
basis of the treating physician’s preference to receive 28- and
21-day regimens of gemcitabine plus carboplatin without
day-15 gemcitabine, and dosages were the same as in the
current trial. Median survival was slightly greater in the study
by Obasaju et al. compared with the current trial. However,
response and toxicity were analogous to this study; the overall
response rate was 22.8% with the 28-day regimen and 32.7%
with the 21-day regimen (favoring the 21-day regimen), but
hematologic toxicity was slightly less with the 28-day regimen.
The carboplatin plus gemcitabine regimen is associated
with a low rate of febrile neutropenia compared with taxane-
based regimens. In addition, carboplatin plus gemcitabine
rarely results in alopecia; only 5% of patients enrolled in the
current study experienced grade 2 alopecia, and no severe
neurotoxicity was reported in this trial. This compares favor-
ably with other commonly used doublets in advanced
NSCLC, including carboplatin plus paclitaxel33 or cisplatin
plus taxotere34 or vinorelbine.35 Toxicity consideration, in-
cluding alopecia and neurotoxicity, may be important deter-
minants of regimen selection when the efficacy of available
regimens is similar. An ongoing randomized trial is compar-
ing carboplatin plus gemcitabine to paclitaxel doublets in
advanced NSCLC.36
Previous research has focused more attention on the use of
a 21-day regimen,12,17,28–30 primarily because of the hemato-
logic toxicity associated with older 28-day regimens (which
included day-15 gemcitabine). Although the newer 28-day reg-
imen studied by our regimen (minus day-15 gemcitabine) is
comparable in efficacy and toxicity to the 21-day regimen, in
practice, we have continued to favor 21-day administration of
gemcitabine and carboplatin. The 21-day regimen may offer
more consistent dose density (this regimen was associated with
fewer dose reductions or interruptions) and a shorter duration of
chemotherapy when compared with the 28-day regimen.
Although baseline characteristics in this study were
generally comparable between treatment arms, 16 of 52
patients had squamous cell histology with the 21-day regi-
men, compared with 7 of 48 patients with the 28-day regi-
men. It is unclear whether this discrepancy biased the results
of this study in any way. Also, as with most phase II studies,
no information on poststudy chemotherapy was collected in
this study. Although it is likely that many patients in this
study went on to receive additional lines of therapy, it is
unclear whether such therapy favored either arm of the study.
We conclude that either schedule of gemcitabine plus
carboplatin evaluated in the current trial is active, well toler-
ated, and may serve as a backbone for the integration of
targeted agents and investigation in earlier stages of this
disease, including the adjuvant setting. In a recent study, the
addition of exisulind to a 21-day gemcitabine and carboplatin
regimen produced no apparent benefit over standard chemo-
therapy; however, this combination was well tolerated, with
mainly hematologic toxicities.37 Further trial results are
awaited on the benefits of incorporating bevacizumab and
TABLE 3. Summary of Toxicity
28-Day Regimen (n  48) 21-Day Regimen (n  52)
Hematologic Grade 3 (%) Grade 4 (%) Grade 3/4 (%) Grade 3 (%) Grade 4 (%) Grade 3/4 (%)
Anemia 2 (4.2) 0 2 (4.2) 10 (19.2) 3 (5.8) 13 (25.0)
Neutropenia 10 (20.8) 3 (6.3) 13 (27.1) 12 (23.1) 13 (25.0) 25 (48.1)
Neutropenic fever 0 0 0 1 (1.9) 0 1 (1.9)
Thrombocytopenia 16 (33.3) 2 (4.2) 18 (37.5) 25 (48.1) 1 (1.9) 26 (50.0)
Leukopenia 7 (14.6) 3 (6.3) 11 (22.9) 14 (26.9) 7 (13.5) 21 (40.4)
Nonhematologic
Alopecia* 0 0 0 0 0 0
Rash 1 (2.1) 0 1 (2.1) 1 (1.9) 0 1 (1.9)
Nausea/vomiting 5 (10.4) 0 8 (16.7) 2 (3.8) 0 2 (3.8)
Infection 1 (2.1) 0 1 (2.1) 2 (3.8) 0 2 (3.8)
Fatigue 3 (6.3) 0 3 (6.3) 5 (9.6) 0 5 (9.6)
*Grade 2 alopecia was experienced by three patients (6.3%) with on the 28-day regimen and two patients (3.8%) on the 21-day regimen.
TABLE 4. Summary of Trials Using Similar Schedules and








Carratto et al. (12) 56 48 13
Edelman et al. (38) 37 25 10
Obasaju et al. (32) 193 33 12
28-day schedules
Iaffaioli et al. (14) 38 50 16
Mott et al. (31) 30 10 8.3
Obasaju et al. (32) 211 23 9.8
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other vascular endothelial growth factor or epidermal growth
factor pathway inhibitors to gemcitabine and carboplatin in
advanced NSCLC.
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